

Fluzone® Intradermal (Influenza Virus Vaccine) Fact Sheet

About Fluzone Intradermal Vaccine

- Fluzone Intradermal vaccine, the only intradermal influenza vaccine approved by the U.S. Food and Drug Administration, is an inactivated influenza virus vaccine given to people 18 through 64 years of age for active immunization against influenza disease caused by influenza virus subtypes A and type B contained in the vaccine.¹
- Fluzone Intradermal vaccine has a 90 percent smaller needle. This microneedle only goes as deep as the skin's surface using an ultra-thin tip (1.5 mm long) that is the same thickness as a U.S. penny.¹
- Fluzone Intradermal vaccine contains less vaccine than the traditional flu shot (0.1mL compared to 0.5mL).¹

About Intradermal Microinjection

- Intradermal vaccines are injected into the skin through a small, ultra-thin needle. Because the skin has more immune cells than the muscle, an intradermal vaccine is able to use the skin's natural defenses.¹

Fluzone Intradermal Vaccine Availability

- Fluzone Intradermal vaccine is now available to patients for immunizations administered during the upcoming 2012-2013 influenza season.
- Visit www.Fluzone.com for more information.

About Influenza and Vaccination

- Influenza is a serious respiratory illness that is easily spread and can lead to severe complications, even death.^{2,3} Each year in the U.S., 1 in 5 people, or up to 20 percent of the population gets the flu and an estimated 226,000 people are hospitalized from influenza-related complications.^{3,4}
- Depending on virus severity during the influenza season, annual deaths can range from a low of 3,000 to a high of about 49,000 people.⁴
 - Combined with pneumonia, influenza is the nation's ninth leading cause of death.⁵
- The Centers for Disease Control and Prevention (CDC) recommends everyone six months of age and older receive an annual flu shot.³
- A recent telephone survey of 663 adults 18 through 64 years of age revealed that three-in-five (61 percent) adults 18 through 64 years of age do not get their annual flu vaccination. This is an unexpectedly low rate considering 67 percent of these adults indicated they are afraid of spreading the flu to their family and friends. This shows a disconnect between fear and action.
- In this same survey, 53 percent of adults 18 through 64 years of age who were vaccinated annually reported that their vaccination experience would be better if the needle was much smaller, and 65 percent said their experience would be better if access to the flu shot was more convenient.
- The single most important thing adults can do to help prevent getting or spreading the flu is to get their annual flu vaccination.³

Important Safety Information

Redness, firmness, swelling, and itching at the injection site occur more frequently with Fluzone Intradermal vaccine than with FLUZONE vaccine. Other common side effects to Fluzone Intradermal vaccine include pain, headache, fatigue, and muscle aches. Side effects other than those listed above may occur. Fluzone Intradermal vaccine should not be administered to anyone with a severe allergic reaction to any vaccine component, including eggs, egg products, or to a previous dose of any influenza vaccine. Tell the doctor if you have ever experienced Guillain-Barré syndrome (severe muscle weakness) after a previous dose of influenza vaccine. If you notice any other problems or symptoms following vaccination, please contact your health care professional immediately. Vaccination with Fluzone Intradermal vaccine may not protect all individuals.

For more information about Fluzone Intradermal vaccine, talk to your health care professional or pharmacist and see complete Patient Information at www.Fluzone.com.

About Survey

The survey results are from GfK Roper's weekly telephone omnibus service, OmniTel. Interviewing was conducted from June 1- 3, 2012. A total of 1005 interviews with adults aged 18+ were completed, with 663 among the target subgroup of adults aged 18-64. The margin of error for this study is +/- 3 percentage points for total sample and is higher for subgroups.

This survey was sponsored by Sanofi Pasteur, the vaccines division of Sanofi.

References

1. Fluzone Intradermal vaccine [Prescribing Information]. Swiftwater, PA: Sanofi Pasteur Inc.; 2012.
2. CDC. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. *MMWR*. 2010;59(RR-8):1-62.
3. CDC. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2011. *MMWR*. 2011;60(30):1128-1132.
4. CDC. Estimates of deaths associated with seasonal influenza – United States, 1976-2007. *MMWR*. 2010;59(33):1057-1062.
5. CDC. Deaths: Final data for 2006. National vital statistic reports. 2010. http://www.cdc.gov/nchs/data/nvsr/nvsr60/nvsr60_04.pdf. Accessed August 29, 2012.

###